EUVIMEDEUVIMED entdecken
Crossref

Clinical Implementation Study of Genetic Risk-Based Breast Cancer Screening

Madli Tamm, Peeter Padrik, Kristiina Ojamaa, Anette Paas, Anni Lepland, Krista Kruuv-Käo, Liis Leitsalu, Siim Sõber, Laura Roht, Sander Pajusalu, Tiina Kahre, Anna Padrik und 14 weitere

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2025.08.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Madli Tamm und 25 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Genomics, University of Tartu, Tartu, Estonia. Hauptthemen laut MEDLINE: Breast Neoplasms, Early Detection of Cancer, Genetic Testing, Genetic Predisposition to Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: European Commission, EIT Health, European Institute of Innovation and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Breast cancer (BC) remains the most common type of cancer and the leading cause of cancer-related deaths in women despite the widespread screening programs and personalized treatment options. Current age-based screening programs are suboptimal missing high-risk young women. The "Be RIGHT with breast cancer risk management" (BRIGHT) study evaluated a genetic risk-based personalized BC screening service model in real-world healthcare settings, focusing on younger women excluded from standard screening. METHODS: The BRIGHT study included 800 healthy Estonian women aged 35 to 49 using telemedicine and home-based testing. Participants underwent polygenic risk score (PRS) testing and based on the questionnaire those meeting the monogenic pathogenic variant (MPV) testing criteria were referred to clinical geneticists. All women received personalized genetic risk-based clinical recommendations, and if needed, referral to BC screening. Participants' and healthcare professionals' feedback was collected. RESULTS: 330 (41.3%) women with elevated polygenic risk received recommendations to start screening earlier than the current standard. 124 (15.5%) women were advised to begin BC screening immediately, among whom one was diagnosed with stage 0 cancer and one with a precancerous lesion. Of the 90 participants completing MPV testing, four (4.4%) were MPV-positive. Feedback indicated high satisfaction with the digital approach and a clear understanding of results and recommendations. CONCLUSIONS: The study demonstrated the feasibility and acceptability of a personalized genetic risk-based BC screening model. It has the potential to enhance BC screening programs, particularly for younger women and those at higher genetic risk, while avoiding unnecessary interventions for low-risk individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsEarly Detection of CancerGenetic TestingGenetic Predisposition to DiseaseHumansFemaleAdultMiddle AgedRisk AssessmentTelemedicineEstonia

Stichwörter der Autor:innen

Early detectionGenetic risk assessmentPersonalized screeningPolygenic risk scoreTelemedicine

Autor:innen und Institutionen

  • Institute of Genomics, University of Tartu, Tartu, Estonia.
  • OÜ Antegenes, Tartu, Estonia; Haematology and Oncology Clinic, Tartu University Hospital, Tartu, Estonia.
  • Haematology and Oncology Clinic, Tartu University Hospital, Tartu, Estonia.
  • OÜ Antegenes, Tartu, Estonia.
  • Genetics and Personalized Medicine Clinic, Tartu University Hospital, Tartu, Estonia.
  • Institute of Genomics, University of Tartu, Tartu, Estonia; Genetics and Personalized Medicine Clinic, Tartu University Hospital, Tartu, Estonia.

Förderung

  • European Commission
  • EIT Health
  • European Institute of Innovation and Technology
  • Tartu Ülikool
  • Estonian Research Council

Zitieren

APA

Tamm, M., Padrik, P., Ojamaa, K., Paas, A., Lepland, A., Kruuv-Käo, K., Leitsalu, L., Sõber, S., Roht, L., Pajusalu, S., Kahre, T., Padrik, A., Pindmaa, J., Luga, K., Rootslane, L., Ilves, A., Ulp, S., Kallak, K., Tihamäe, A. T., …, & Tõnisson, N. (2026). Clinical Implementation Study of Genetic Risk-Based Breast Cancer Screening. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.08.021

Vancouver

Tamm M, Padrik P, Ojamaa K, Paas A, Lepland A, Kruuv-Käo K, et al. Clinical Implementation Study of Genetic Risk-Based Breast Cancer Screening. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2025.08.021

BibTeX
@article{Tamm2026,
  author = {Tamm, Madli and Padrik, Peeter and Ojamaa, Kristiina and Paas, Anette and Lepland, Anni and Kruuv-Käo, Krista and Leitsalu, Liis and Sõber, Siim and Roht, Laura and Pajusalu, Sander and Kahre, Tiina and Padrik, Anna and Pindmaa, Jagnar and Luga, Kadri and Rootslane, Ly and Ilves, Anne and Ulp, Sulev and Kallak, Kersti and Tihamäe, Ave-Triin and Feldman, Inna and Sampaio, Filipa and Costa, Luís and Nogueira-Costa, Gonçalo and Österman, Tiina and Rosenmöller, Magda and Tõnisson, Neeme},
  title = {Clinical Implementation Study of Genetic Risk-Based Breast Cancer Screening},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2025.08.021}
}
Kostenlos starten →